siltuximab   Click here for help

GtoPdb Ligand ID: 7396

Synonyms: cLLB8 | CNTO 328 | Sylvant®
Approved drug Immunopharmacology Ligand
siltuximab is an approved drug (EMA & FDA (2014))
Compound class: Antibody
Comment: Siltuximab is a monoclonal antibody targeting interleukin 6 (IL-6) [2].
Peptide sequences for the heavy and light chains of this antibody are annotated in its IMGT/mAb-DB record. The invention of siltuximab is covered by patent US7291721 [1].
No information available.
Summary of Clinical Use Click here for help
Approved to treat multicentric Castleman's disease (MCD, a.k.a. giant lymph node hyperplasia), a rare blood disorder.

SARS-CoV-2 and COVID-19: Siltuximab is being investigated as a mechanism to combat cytokine storm resulting from an exaggerated response of the immune system in patients with severe COVID-19.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Interleukin-6 (IL-6) has emerged as a key factor in the pathogenesis of multicentric Castleman’s disease (MCD) [3]. Siltuximab is an anti-IL-6 monoclonal antibody which ameliorates the IL-6-induced increase in immunoglobulin-producing cells and production of acute phase proteins associated with MCD [2].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04329650 Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia Phase 2 Interventional Fundacion Clinic per a la Recerca Biomédica
NCT04330638 Treatment of COVID-19 Patients With Anti-interleukin Drugs Phase 3 Interventional University Hospital, Ghent
External links Click here for help